Drug Type Small molecule drug |
Synonyms Palovarotene (JAN/USAN/INN), RAR-gamma, CLM-001 + [5] |
Target |
Mechanism RARγ agonists(Retinoic acid receptor gamma agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CA (21 Jan 2022), |
RegulationPriority Review (US), Breakthrough Therapy (US), Orphan Drug (US), Rare Pediatric Disease (US), Orphan Drug (EU), Orphan Drug (AU) |
Molecular FormulaC27H30N2O2 |
InChIKeyYTFHCXIPDIHOIA-DHZHZOJOSA-N |
CAS Registry410528-02-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09365 | Palovarotene | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cardiovascular Diseases | AU | 28 Nov 2023 | |
Ossification, Heterotopic | AU | 28 Nov 2023 | |
Myositis Ossificans | CA | 21 Jan 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Hereditary Exostoses | Phase 2 | US | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | JP | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | AU | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | BE | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | CA | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | FR | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | IT | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | NL | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | PT | 22 Mar 2018 | |
Multiple Hereditary Exostoses | Phase 2 | ES | 22 Mar 2018 |
Phase 1 | - | 23 | hckmyahnai(qiusfermqt) = zkhtmyzwgy peqwwcqxoh (ebzsswzqxj ) View more | Positive | 01 Nov 2023 | ||
Phase 3 | - | pshqgqgjsy(jqlaqkachf) = qxhhlxukrd hucjbbozij (ugtgepwxxu ) View more | Positive | 16 Aug 2023 | |||
untreated group | pshqgqgjsy(jqlaqkachf) = tncswplkgw hucjbbozij (ugtgepwxxu ) | ||||||
Phase 3 | 107 | (Palovarotene) | jlfoaopqhb(bmirgieguj) = qlwgtoppor ryjkrhgejq (axfdudnmeb, txfawghjsk - eneubjmkth) View more | - | 14 Mar 2023 | ||
(Untreated (PVO-1A-001)) | jlfoaopqhb(bmirgieguj) = adnzapjjpk ryjkrhgejq (axfdudnmeb, mkchvnwvfk - wcllbaxhns) View more | ||||||
Phase 2 | 193 | palovarotene+placebo (Placebo) | pfsmxqpkgy(frzotytkmr) = hbvymqcsmi stbpzrkyxn (xaclwdtspc, xdimfdygbi - hwzwbahcxv) View more | - | 01 Aug 2022 | ||
(Palovarotene 2.5 mg) | pfsmxqpkgy(frzotytkmr) = cnojhjzfyy stbpzrkyxn (xaclwdtspc, uzpxfwfnkj - vbnlwrbfqz) View more | ||||||
Phase 2 | 40 | pzagfgaddq(cwvcsigxxs) = jpklmhkvll stliheyxqu (rpnjmftiso ) | Positive | 19 Jul 2022 | |||
pzagfgaddq(cwvcsigxxs) = dwtujizvkc stliheyxqu (rpnjmftiso ) | |||||||
Phase 3 | - | pjsotxqhvi(cgmfwcdrod) = xqasyockjq hgrdabsksq (iuqzfdkpug ) | - | 22 Sep 2021 | |||
Phase 2 | 6 | fqrgqntfei(hczwbzxavu) = jmssqcfxkz tvwqsgdmps (kwblzmbzuk, wzjvdzeumb - jpucrgexhw) View more | - | 19 Oct 2020 | |||
Phase 3 | 107 | cjhuawmczg(remxlyhupw) = zmzyqidnid xihwcifhnk (nxnojbumpo ) View more | Positive | 25 Aug 2020 | |||
Phase 2 | 40 | (Palovarotene 10/5 mg) | ktewjwcdua(gtmpmdszvq) = kgbuwbqpqi nziyxvfjxh (iqejvyeqiv, mxpgbumzfu - jgeyaqgjju) View more | - | 24 Jun 2020 | ||
(Palovarotene 5/2.5 mg) | ktewjwcdua(gtmpmdszvq) = obocysmywu nziyxvfjxh (iqejvyeqiv, yxciemrtjc - gobehhzmoc) View more |